Navigation Links
Pre-emptive treatment helped curtail skin toxicity with panitumumab
Date:1/16/2009

(PHILADELPHIA) With a pre-emptive, prophylactic skin regimen, patients who receive panitumumab for treatment of metastatic colorectal cancer may be able to avoid some of the skin-associated toxicities, according to data presented at the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.

Edith Mitchell, M.D., a clinical professor in the Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, presented data from the study, which was the first prospective study to compare pre-emptive and reactive skin treatment for skin toxicities related to panitumumab. The study was co-led by Dr. Mitchell and Mario Lacouture, M.D., an assistant professor of Dermatology at Northwestern University's Feinberg School of Medicine in Chicago.

Skin toxicities are the most common adverse effects related to panitumumab, which is a fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR). The toxicities could include erythema, dermatitis, pruritus, pustules, rash, and hair and nail changes.

"Panitumumab and the other EGFR inhibitors are now key components to the treatment strategies for metastatic colorectal cancer," Dr. Mitchell said. "But the majority of the patients who receive these agents suffer from skin toxicities, and for some patients, the treatment must be interrupted or discontinued. If we can prevent or minimize these toxicities, it would be a significant advance in patient care."

The researchers studied 95 patients receiving panitumumab in combination with irinotecan-based chemotherapy. The patients were randomized to receive pre-emptive skin toxicity treatment initiated 24 hours prior to the first dose of panitumumab, then given daily through week six, or reactive skin treatment after the skin toxicity developed. The skin treatment included moisturizers, sunscreen, topical steroids and oral doxycycline.

The primary endpoint was the incidence of specific grade 2 or higher skin toxicities during the six week skin treatment period. The incidence of these toxicities was reduced more than 50% in the group that received pre-emptive treatment.

Quality of life was also assessed, using the Dermatology Life Quality Index. Patients who received the pre-emptive, prophylactic skin treatment regimen reported an improved quality of life, even around week three, which was the median time to first grade 2 or higher skin toxicity in the reactive skin treatment group.

"This study supports the notion that, as with other side effects to cancer treatments, it is more advantageous to treat prophylactically, than to wait for the side effect to fully develop," Dr. Lacouture said. "Futhermore, it shows that treating early on does not affect the benefit received from the anticancer therapy."


'/>"/>

Contact: Emily Shafer
emily.shafer@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Targeted Prostate Cancer Biopsy and Cancer Treatment Earns Acceptance From Nations Top Prostate Specialists
2. A Study In This Months Journal Of Nervous And Mental Disease Reveals Hope For Recovery From Suicidal Thinking And Treatment Resistant Mental Illness
3. Video: Solta Medical Introduces Advanced Thermage Body Tip 16.0 for Faster Body Shaping and Contouring Treatments
4. Estonian Cancer Patients Have Access to More Conformal Radiotherapy Treatments for First Time with Unveiling of Advanced Varian Treatment Machine
5. IVF Treatments Often Work for Women Under 35
6. PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine
7. Frost & Sullivan Recognizes Neotropixs Approach to the Treatment of Small Cell Lung Cancer and Neuroendocrine Cancers
8. Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
9. Irishman with Peripheral Arterial Disease (P.A.D.) Finds Leg-, Life-Saving Treatment In Columbus, Ohio
10. Popular cold and cough treatment may create respiratory distress in young children
11. SNM praises CMS decision to expand reimbursement for cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... , ... Cheerag D. Upadhyaya , M.D., M.Sc., FAANS has been appointed ... part of Saint Luke’s Health System . Dr. Upadhyaya has served in the ... FAANS joins Stanley P. Fisher, M.D., who has served as medical co-director ...
(Date:7/24/2017)... ... July 24, 2017 , ... A four alarm fire ... site and threatened numerous homes and businesses nearby, causing some 700 individuals to ... Los Angeles Area consulting firm Fire Protection Group, Inc. notes that the report ...
(Date:7/24/2017)... ... 24, 2017 , ... The Topricin Companies, formerly Topical Biomedics, ... revolutionary, natural, after-burn skin care product, Topricin After Burn Cream. , ... skin conditions, including cancer. In the short term, overexposure to sun, wind ...
(Date:7/24/2017)... ... 24, 2017 , ... The 2017 NCSL International Workshop & ... focuses on the new ISO/IEC 17025 standards. This marks the first time in ... calibration will be changed. , As an exhibitor, METTLER TOLEDO will showcase ...
(Date:7/24/2017)... ... 24, 2017 , ... The Magic Wand® Rechargeable, the top-of-the-line ... favorite sex toy. Created in collaboration with website Kinkly.com, the award was the ... The Magic Wand Rechargeable won in stiff competition from brands such as Lelo, ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... LAS VEGAS , July 13, 2017 It ... the United States is in the midst of ... Disease Control , since 1999, the number of overdose deaths ... , "resulting in over half a million dead from 2001 ... like codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a ...
(Date:7/12/2017)... 12, 2017  Eli Lilly and Company (NYSE: ... companies to resolve pending patent litigation in the U.S. District ... regarding the Cialis ® (tadalafil) unit dose patent. ... 2020. As part of the agreement, Cialis exclusivity is now ... "The unit dose patent for Cialis is valid ...
(Date:7/11/2017)... , July 11, 2017  Dr. Echenberg, founder of Echenberg Institute, ... program to patients who suffer from painful intercourse and other painful pelvic ... vaginal atrophy due to menopause. ... VuVatech LLC ... created by Sarasota, Florida -based start-up company, VuVatech LLC, ...
Breaking Medicine Technology: